AR056202A1 - Nucleosidos modificados en 4' como agentes antivirales - Google Patents
Nucleosidos modificados en 4' como agentes antiviralesInfo
- Publication number
- AR056202A1 AR056202A1 ARP060104218A ARP060104218A AR056202A1 AR 056202 A1 AR056202 A1 AR 056202A1 AR P060104218 A ARP060104218 A AR P060104218A AR P060104218 A ARP060104218 A AR P060104218A AR 056202 A1 AR056202 A1 AR 056202A1
- Authority
- AR
- Argentina
- Prior art keywords
- nhr4
- optionally substituted
- value
- unsubstituted
- nr4nh2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos, métodos y composiciones para tratar un huésped infectado con virus de inmunodeficiencia humana y virus de hepatitis B, método que comprende administrar una cantidad efectiva de un 4'-C-substituido-b-D- y b-L-nucleosido o una sal o prodroga farmacéuticamente aceptable del mismo. Reivindicacion 1: Un compuesto caracterizado porque comprende un b-D- y b-L-nucleosido o una sal o prodroga farmacéuticamente aceptable del mismo, que tiene una estructura definida por la formula (1) o por la formula (2), donde X es hidrogeno, F, Cl, Br, I, NH2, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4, SH, SR4, S(O)bR4, OH, OR4, N3, CN, o CF3; Y es hidrogeno, F, Cl, Br, I, NH2, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4, SH, SR4, S(O)bR4, OH, OR4, N3, CN, CF3, hidroximetilo, metilo, etilo opcionalmente substituido o no substituido, vinilo opcionalmente substituido o no substituido, 2-bromovinilo opcionalmente substituido o no substituido, etinilo opcionalmente substituido o no substituido; R1 es F o N3; R2 es OH, OR4, OC(O)R4, OPvO3vMxR4yR5z, PvO3vMxR4yR5z, OCH2PvO3vMxR4yR5z, OP(O)(OQ)a(NHR4)b, SH, SR4, S(O)bR4, SC(O)R4, NH2, NHC(O)R4, NHR4, NR4R5, NHOH, NHOR4, NHNH2, NR4NH2, NHNHR4; R3 es F, ciano, azido, etinilo, clorovinilo, fluorovinilo, alquilo C1-6, alquilo C1-6 substituido con uno a tres átomos de halogeno, alquenilo C1-6 o alquinilo C1-6 con la condicion que cuando R1 es N3, entonces R3 no es hidroximetilo; Z es O, S, CH2 o C=CH2; A es N, CH, o CF; y R4 y R5 son iguales o diferentes y son alquilo inferior, alquenilo inferior, acilo de 1-17 átomos de carbono, arilo, o aralquilo; M es al menos un miembro seleccionado del grupo formado por H+, Na+, y K+; v tiene un valor de 1, 2, o 3; x, y, y z son independientes entre sí y tienen un valor de 0, 1, 2, 3 o 4; y a tiene un valor de 0 o 1, b tiene un valor de 1 o 2, y Q es M o R4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72038805P | 2005-09-26 | 2005-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056202A1 true AR056202A1 (es) | 2007-09-26 |
Family
ID=37900393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104218A AR056202A1 (es) | 2005-09-26 | 2006-09-27 | Nucleosidos modificados en 4' como agentes antivirales |
Country Status (17)
Country | Link |
---|---|
US (1) | US8569478B2 (es) |
EP (2) | EP3159351A3 (es) |
JP (1) | JP2009510075A (es) |
KR (1) | KR20080065272A (es) |
CN (2) | CN102924549A (es) |
AR (1) | AR056202A1 (es) |
AU (1) | AU2006294807B2 (es) |
BR (1) | BRPI0616738A2 (es) |
CA (2) | CA2623522C (es) |
EA (1) | EA200800932A1 (es) |
ES (1) | ES2617582T3 (es) |
IL (1) | IL190390A0 (es) |
NZ (3) | NZ567272A (es) |
PT (1) | PT1937825T (es) |
UY (1) | UY29868A1 (es) |
WO (1) | WO2007038507A2 (es) |
ZA (1) | ZA200802723B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′-支链核苷和黄病毒突变 |
RU2358979C2 (ru) | 2003-05-30 | 2009-06-20 | Фармассет, Инк. | Модифицированные фторированные аналоги нуклеозида |
CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
WO2009052050A1 (en) * | 2007-10-15 | 2009-04-23 | Pharmasset, Inc. | Dioxolane thymine phosphoramidates as anti-hiv agents |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
KR20110104074A (ko) | 2008-12-23 | 2011-09-21 | 파마셋 인코포레이티드 | 퓨린 뉴클레오시드의 합성 |
PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EP2513131A4 (en) * | 2009-12-17 | 2013-10-16 | Medivir Ab | NOVEL 3'-DEOXY-3'-METHYLIDENE-L-NUCLEOSIDES |
CA2794671C (en) | 2010-03-31 | 2018-05-01 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
CN106166160A (zh) | 2011-09-16 | 2016-11-30 | 吉利德制药有限责任公司 | 用于治疗hcv的组合物 |
AR089650A1 (es) | 2011-10-14 | 2014-09-10 | Idenix Pharmaceuticals Inc | Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales |
SG11201407674TA (en) | 2012-05-22 | 2014-12-30 | Idenix Pharmaceuticals Inc | D-amino acid compounds for liver disease |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EP2852583A1 (en) | 2012-05-23 | 2015-04-01 | Bristol-Myers Squibb Company | Sulfilimine and sulphoxide methods for producing festinavir |
AR091156A1 (es) | 2012-05-25 | 2015-01-14 | Jansen R & D Ireland | Nucleosidos de espirooxetano de uracilo |
US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
TR201809048T4 (tr) | 2012-10-08 | 2018-07-23 | Centre Nat Rech Scient | Hcv enfeksiyonu için 2'-kloro nükleosit analogları. |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
US20140212491A1 (en) | 2013-01-31 | 2014-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
EP2986602A1 (en) | 2013-04-16 | 2016-02-24 | Bristol-Myers Squibb Company | Method for producing festinavir using 5-methyluridine as starting material |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
US20160130260A1 (en) | 2013-06-13 | 2016-05-12 | Bristol-Myers Squibb Company | Tert-butyl sulphoxide method for producing festinavir |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
SG10201804835VA (en) | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
KR101718242B1 (ko) * | 2015-11-25 | 2017-03-21 | 주식회사 타미온 | Hiv 억제 활성을 가지는 신규한 화합물 및 이의 용도 |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
CN111995649A (zh) * | 2020-04-09 | 2020-11-27 | 瀚海新拓(杭州)生物医药有限公司 | 一种蝶啶酮核苷酸类似物及其药物组合物、制备方法和医药用途 |
CN113501853B (zh) * | 2021-09-13 | 2021-12-07 | 南京颐媛生物医学研究院有限公司 | 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途 |
WO2023085242A1 (ja) * | 2021-11-12 | 2023-05-19 | 国立大学法人北海道大学 | 抗ウイルス剤 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
DD262802A5 (de) | 1985-09-17 | 1988-12-14 | The Wellcome Foundation Limited,Gb | Verfahren zur herstellung einer pharmazeutischen formulierung |
JPH02500364A (ja) | 1986-11-21 | 1990-02-08 | マツクス‐プランク‐ゲゼルシヤフト ツール フエルデルング デル ヴイツセンシヤフテン エー フアウ | ヒトにおけるウイルス感染の治療法およびそのための組成物 |
DE3739366A1 (de) * | 1987-04-10 | 1988-10-27 | Boehringer Mannheim Gmbh | Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel |
JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質 |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
NZ228645A (en) | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
US5041449A (en) | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
SE464168B (sv) | 1989-07-19 | 1991-03-18 | Bo Fredrik Oeberg | Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt) |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
AU7623991A (en) | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
JPH05507279A (ja) | 1990-05-29 | 1993-10-21 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | グリセロールジ―およびトリホスフェート誘導体の合成 |
DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
US5817799A (en) * | 1990-07-23 | 1998-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5414078A (en) * | 1991-04-05 | 1995-05-09 | Emory University | Preparation of 3'-substituted-2',3'-dideoxynucleosides and 2'-deoxynucleosides from acyclic, achiral precursors |
EP0594677A4 (en) | 1991-07-12 | 1997-09-17 | Vical Inc | Antiviral liponucleosides: treatment of hepatitis b |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
DE4207363A1 (de) * | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung |
AU701574B2 (en) | 1993-05-12 | 1999-02-04 | Karl Y. Hostetler | Acyclovir derivatives for topical use |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
DE19632823C1 (de) * | 1996-08-14 | 1997-11-20 | Symbio Herborn Group Gmbh & Co | Komplexe zwischen S-(+)-Adenosylmethionin und 3'-Azido-2',3'-didesoxynucleosid als potente Inhibitoren der HIV-Replikation |
FI107059B (fi) * | 1998-07-01 | 2001-05-31 | Metso Paper Inc | Paperikoneen formeri-puristinosa ja menetelmä rainan siirtämiseksi formerilta puristinosalle |
ATE250623T1 (de) | 1999-05-12 | 2003-10-15 | Yamasa Corp | 4'-c-ethynyl-purin-nukleoside |
BR0210594A (pt) | 2001-06-22 | 2005-11-01 | Pharmasset Ltd | (beta)-d ou (beta)-l-3-halonucleosìdeo |
EP1653976A4 (en) * | 2003-02-19 | 2009-07-29 | Univ Yale | ANTIVIRAL NUCLEOSIDE ANALOGUES AND METHODS FOR TREATING VIRAL INFECTIONS, IN PARTICULAR HIV INFECTIONS |
RU2358979C2 (ru) | 2003-05-30 | 2009-06-20 | Фармассет, Инк. | Модифицированные фторированные аналоги нуклеозида |
US20090318380A1 (en) * | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
-
2006
- 2006-09-26 NZ NZ567272A patent/NZ567272A/en not_active IP Right Cessation
- 2006-09-26 EA EA200800932A patent/EA200800932A1/ru unknown
- 2006-09-26 CN CN2012103530710A patent/CN102924549A/zh active Pending
- 2006-09-26 EP EP16201801.4A patent/EP3159351A3/en not_active Withdrawn
- 2006-09-26 NZ NZ597544A patent/NZ597544A/xx not_active IP Right Cessation
- 2006-09-26 US US12/067,995 patent/US8569478B2/en active Active
- 2006-09-26 CN CNA2006800423211A patent/CN101310021A/zh active Pending
- 2006-09-26 KR KR1020087009645A patent/KR20080065272A/ko active Search and Examination
- 2006-09-26 CA CA2623522A patent/CA2623522C/en not_active Expired - Fee Related
- 2006-09-26 ES ES06825120.6T patent/ES2617582T3/es active Active
- 2006-09-26 EP EP06825120.6A patent/EP1937825B1/en active Active
- 2006-09-26 BR BRPI0616738-1A patent/BRPI0616738A2/pt not_active Application Discontinuation
- 2006-09-26 CA CA2904692A patent/CA2904692A1/en not_active Abandoned
- 2006-09-26 JP JP2008533517A patent/JP2009510075A/ja active Pending
- 2006-09-26 PT PT68251206T patent/PT1937825T/pt unknown
- 2006-09-26 WO PCT/US2006/037470 patent/WO2007038507A2/en active Application Filing
- 2006-09-26 AU AU2006294807A patent/AU2006294807B2/en not_active Ceased
- 2006-09-26 NZ NZ609146A patent/NZ609146A/en not_active IP Right Cessation
- 2006-09-27 AR ARP060104218A patent/AR056202A1/es unknown
- 2006-10-17 UY UY29868A patent/UY29868A1/es not_active Application Discontinuation
-
2008
- 2008-03-24 IL IL190390A patent/IL190390A0/en unknown
- 2008-03-27 ZA ZA200802723A patent/ZA200802723B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200802723B (en) | 2009-03-25 |
NZ597544A (en) | 2013-04-26 |
UY29868A1 (es) | 2007-04-30 |
KR20080065272A (ko) | 2008-07-11 |
IL190390A0 (en) | 2008-11-03 |
PT1937825T (pt) | 2017-03-08 |
EP1937825B1 (en) | 2016-12-21 |
BRPI0616738A2 (pt) | 2011-06-28 |
EP1937825A2 (en) | 2008-07-02 |
US8569478B2 (en) | 2013-10-29 |
NZ567272A (en) | 2012-02-24 |
ES2617582T3 (es) | 2017-06-19 |
CA2623522C (en) | 2015-12-08 |
AU2006294807B2 (en) | 2013-01-17 |
CN102924549A (zh) | 2013-02-13 |
AU2006294807A1 (en) | 2007-04-05 |
US20110021454A1 (en) | 2011-01-27 |
CN101310021A (zh) | 2008-11-19 |
CA2904692A1 (en) | 2007-04-05 |
EP1937825A4 (en) | 2010-06-23 |
EA200800932A1 (ru) | 2008-10-30 |
EP3159351A3 (en) | 2017-05-17 |
CA2623522A1 (en) | 2007-04-05 |
EP3159351A2 (en) | 2017-04-26 |
JP2009510075A (ja) | 2009-03-12 |
WO2007038507A2 (en) | 2007-04-05 |
NZ609146A (en) | 2014-08-29 |
WO2007038507A3 (en) | 2007-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056202A1 (es) | Nucleosidos modificados en 4' como agentes antivirales | |
RU2358979C2 (ru) | Модифицированные фторированные аналоги нуклеозида | |
CY1121639T1 (el) | Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων | |
HN2006041184A (es) | Metodos y estuches para dosificar nucleosidos antivirales beta-d-2 3- didehydro-2 , 3-dideoxy 5- fluorocytidina | |
DK2203430T3 (da) | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) | |
CY1113450T1 (el) | Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες | |
JP2009536660A5 (es) | ||
CL2011002859A1 (es) | Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c. | |
AR049385A1 (es) | Sulfoniletil fosforodiamidatos | |
CO6361922A2 (es) | Inhibidores del virus de la hepatitis c | |
AR054475A1 (es) | Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion | |
AR063707A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. | |
UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
RS51725B (en) | N-METHYLAMINOMETHYL ISOINDOL COMPOUNDS AND COMPOSITIONS CONTAINING THEM AND USING THE SAME | |
PE20140522A1 (es) | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
RU2651892C3 (ru) | Нуклеозидфосфорамидаты в качестве противовирусных агентов | |
EA200900676A1 (ru) | Ингибиторы вируса гепатита с | |
BR0317094A (pt) | Sal de alumìnio livre de zircÈnio, e, composição antiperspirante | |
EA200970375A1 (ru) | Соединения и способы лечения вируса гепатита с | |
EA201600241A1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты | |
EA201491180A1 (ru) | 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с | |
RU2010140627A (ru) | Производные пирролидина | |
AR063942A1 (es) | Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c | |
EA200901573A1 (ru) | Гетероарилзамещенные тиазолы | |
JP2011516610A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |